1991年Günthert等[1]采用针对大鼠转移性胰腺癌细胞表面糖蛋白的一种单抗,其相关抗原的cDNA序列与CD44同源,后证实为CD44v6,将这种单抗与肿瘤细胞同时注入裸鼠体内,可延缓甚至完全阻断其淋巴结和肺转移灶形成。他们最早提出了CD44v6与肿瘤转移相关,而1998年李祖国等[2]首次证明在肝细胞癌(HCC)细胞中CD44v6可能通 In 1991, Günthert et al [1] used a monoclonal antibody directed against the surface glycoproteins of rat metastatic pancreatic cancer cells. The cDNA sequence of the related antigen was homologous to CD44, and was confirmed to be CD44v6. At the same time, this monoclonal antibody was combined with tumor cells Infused into nude mice can delay or even completely block the formation of lymph nodes and lung metastases. They first proposed CD44v6 associated with tumor metastasis, and in 1998, Li et al [2] for the first time that in hepatocellular carcinoma (HCC) cells CD44v6 possible